Weekly Digest – August 2026 Weekly Digest – August 2026 12 August 2026: Enhertu with Pertuzumab approved in China for 1L HER2-positive metastatic Breast cancer Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab has been approved by China’s NMPA for the […]
Weekly Digest – August 2026 Weekly Digest – August 2026 07 August 2026: Hengrui’s Aiweida receives NMPA approval for HER2-positive Colorectal cancer Hengrui Pharma’s HER2-targeted ADC Aiweida has been approved in China for the treatment of adults with HER2-positive colorectal […]
Weekly Digest – August 2026 Weekly Digest – August 2026 07 August 2026: AbbVie’s Elahere receives Minzdrav approval in Russia for Ovarian, Fallopian tube and Peritoneal cancer AbbVie’s ELAHERE has been approved in Russia for the treatment of epithelial ovarian, […]
Weekly Digest – August 2026 Weekly Digest – August 2026 13 August 2026: Celltrion’s CT-P73 receives US FDA FTD for recurrent/metastatic Cervical cancer Celltrion announced that the U.S. FDA has granted Fast Track designation to CT-P73, a Tissue Factor-targeted ADC, […]
Weekly Digest – August 2026 Weekly Digest – August 2026 10 August 2026: ITM receives Complete Response Letter for ITM-11 ITM announced that the U.S. FDA issued a Complete Response Letter for the NDA of 177Lu-edotreotide, an investigational targeted radiotherapeutic […]
Weekly Digest – August 2026 Weekly Digest – August 2026 13 August 2026: Asieris received FDA IND approval for APL‑2501 for the treatment of advanced Solid tumors Asieris Pharmaceuticals announced that the U.S. FDA has cleared the IND application for […]
